Connor Clark & Lunn Investment Management Ltd. Acquires 65,268 Shares of USANA Health Sciences, Inc. $USNA

Connor Clark & Lunn Investment Management Ltd. boosted its holdings in USANA Health Sciences, Inc. (NYSE:USNA) by 202.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 97,537 shares of the company’s stock after buying an additional 65,268 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.52% of USANA Health Sciences worth $2,978,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Linden Thomas Advisory Services LLC bought a new stake in shares of USANA Health Sciences during the 2nd quarter valued at about $246,000. AlphaQuest LLC raised its position in shares of USANA Health Sciences by 168.1% during the second quarter. AlphaQuest LLC now owns 9,146 shares of the company’s stock valued at $279,000 after buying an additional 5,734 shares during the last quarter. First Citizens Bank & Trust Co. purchased a new position in shares of USANA Health Sciences in the second quarter worth $285,000. Ethic Inc. purchased a new position in shares of USANA Health Sciences during the second quarter valued at about $287,000. Finally, Allianz Asset Management GmbH bought a new stake in shares of USANA Health Sciences in the second quarter worth about $638,000. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

USNA has been the topic of a number of research reports. Zacks Research downgraded USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 21st. Wall Street Zen downgraded shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of USANA Health Sciences in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, USANA Health Sciences currently has an average rating of “Reduce” and a consensus price target of $36.00.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, Director Frederic J. Winssinger sold 2,000 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $19.21, for a total value of $38,420.00. Following the sale, the director owned 5,986 shares in the company, valued at $114,991.06. This trade represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John Turman Fleming sold 1,750 shares of the business’s stock in a transaction on Friday, October 31st. The shares were sold at an average price of $19.79, for a total transaction of $34,632.50. Following the sale, the director directly owned 4,565 shares of the company’s stock, valued at $90,341.35. This represents a 27.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 4,807 shares of company stock worth $95,757. Company insiders own 0.63% of the company’s stock.

USANA Health Sciences Stock Down 0.9%

USNA stock opened at $19.20 on Friday. USANA Health Sciences, Inc. has a twelve month low of $18.68 and a twelve month high of $40.78. The stock has a market capitalization of $351.00 million, a price-to-earnings ratio of 21.82, a price-to-earnings-growth ratio of 0.94 and a beta of 0.61. The firm’s fifty day simple moving average is $24.36 and its two-hundred day simple moving average is $28.40.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Thursday, October 9th. The company reported $0.56 EPS for the quarter. USANA Health Sciences had a net margin of 1.86% and a return on equity of 6.96%. The firm had revenue of $200.22 million during the quarter. USANA Health Sciences has set its Q3 2025 guidance at -0.150–0.150 EPS. As a group, equities research analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.